Eliem Therapeutics Stock Today

ELYM Stock  USD 7.22  0.15  2.12%   

Performance

8 of 100

 
Weak
 
Strong
OK

Odds Of Distress

Less than 44

 
High
 
Low
Below Average
Eliem Therapeutics is selling at 7.22 as of the 13th of July 2024; that is 2.12 percent increase since the beginning of the trading day. The stock's lowest day price was 6.83. Eliem Therapeutics has about a 44 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Eliem Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 13th of June 2024 and ending today, the 13th of July 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
10th of August 2021
Category
Healthcare
Classification
Health Care
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. The company has 66.55 M outstanding shares of which 373.28 K shares are currently shorted by private and institutional investors with about 0.52 trading days to cover. More on Eliem Therapeutics

Moving against Eliem Stock

  0.59FLGC Flora Growth CorpPairCorr
  0.54FENC Fennec PharmaceuticalsPairCorr
  0.54IKT Inhibikase TherapeuticsPairCorr
  0.44VRNA Verona Pharma PLC TrendingPairCorr
  0.43VRDN Viridian Therapeutics Buyout TrendPairCorr
  0.39GOSS Gossamer BioPairCorr

Eliem Stock Highlights

ESG Sustainability
Environmental
Governance
Social
Principal ChairmanAndrew MD
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Total Current Liabilities4.1 M2.8 M
Way Up
Slightly volatile
Non Current Liabilities Total35.1 K37 K
Notably Down
Slightly volatile
Total Assets102.2 M110.5 M
Significantly Down
Slightly volatile
Total Current Assets96 M110.3 M
Fairly Down
Slightly volatile
Debt Levels
Eliem Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Eliem Therapeutics' financial leverage. It provides some insight into what part of Eliem Therapeutics' total assets is financed by creditors.
Liquidity
Eliem Therapeutics currently holds 349 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Eliem Therapeutics has a current ratio of 17.13, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Eliem Therapeutics' use of debt, we should always consider it together with its cash and equity.

Total Cashflows From Investing Activities

32.55 Million
Eliem Therapeutics (ELYM) is traded on NASDAQ Exchange in USA. It is located in 23515 NE Novelty Hill Road, Redmond, WA, United States, 98053 and employs 9 people. Eliem Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 472.17 M. Eliem Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 66.55 M outstanding shares of which 373.28 K shares are currently shorted by private and institutional investors with about 0.52 trading days to cover. Eliem Therapeutics currently holds about 122.95 M in cash with (20.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.63.
Check Eliem Therapeutics Probability Of Bankruptcy
Ownership Allocation
30% of Eliem Therapeutics outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change.
Check Eliem Ownership Details

Eliem Stock Institutional Holders

InstituionRecorded OnShares
Millennium Management Llc2024-03-31
20.1 K
Chicago Partners Investment Group Llc2024-03-31
12.1 K
Renaissance Technologies Corp2024-03-31
10.6 K
Advisor Group Holdings, Inc.2024-03-31
8.3 K
Ubs Group Ag2024-03-31
5.9 K
Tower Research Capital Llc2024-03-31
3.6 K
Morgan Stanley - Brokerage Accounts2024-03-31
1.7 K
Qube Research & Technologies2024-03-31
981
Royal Bank Of Canada2024-03-31
63.0
Ra Capital Management, Llc2024-03-31
13.2 M
Bml Capital Management Llc2024-03-31
2.2 M
View Eliem Therapeutics Diagnostics

Eliem Therapeutics Historical Income Statement

At this time, Eliem Therapeutics' Depreciation And Amortization is very stable compared to the past year. As of the 13th of July 2024, Interest Expense is likely to grow to about 3.6 M, while Other Operating Expenses is likely to drop about 30.3 M. View More Fundamentals

Eliem Stock Against Markets

Eliem Therapeutics Corporate Management

Additional Information and Resources on Investing in Eliem Stock

When determining whether Eliem Therapeutics is a strong investment it is important to analyze Eliem Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Eliem Therapeutics' future performance. For an informed investment choice regarding Eliem Stock, refer to the following important reports:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eliem Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
To learn how to invest in Eliem Stock, please use our How to Invest in Eliem Therapeutics guide.
You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eliem Therapeutics. If investors know Eliem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eliem Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.52)
Return On Assets
(0.09)
Return On Equity
(0.13)
The market value of Eliem Therapeutics is measured differently than its book value, which is the value of Eliem that is recorded on the company's balance sheet. Investors also form their own opinion of Eliem Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Eliem Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eliem Therapeutics' market value can be influenced by many factors that don't directly affect Eliem Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eliem Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eliem Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eliem Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.